Anthem Biosciences IPO: Allotment Update and What Investors Should Know
The initial public offering Anthem Biosciences IPO, a prominent player in the biopharmaceutical sector, has drawn strong investor interest, reflecting the growing confidence in India’s life sciences industry. With the subscription period recently concluded, the spotlight now shifts to the IPO allotment process, where investors eagerly await updates on whether they have secured shares.
Anthem Biosciences IPO Overview
Anthem Biosciences, known for its contract research and manufacturing services (CRAMS), launched its IPO to raise capital for expansion, R&D, and debt repayment. The offering witnessed enthusiastic participation from institutional investors, high-net-worth individuals (HNIs), and retail investors, leading to oversubscription across all categories.
Key IPO details:
- Issue Size: Substantial, with both fresh issuance and an offer for sale (OFS) component.
- Price Band: Attractively set, drawing competitive bids.
- Use of Proceeds: Primarily for expanding manufacturing capabilities, strengthening research infrastructure, and reducing borrowings.
Allotment Process of Anthem Biosciences IPO
Following the closure of the subscription window, the IPO allotment process is underway. This phase determines how the available shares are distributed among the applicants. Allotments are based on demand in each category, following regulatory norms and ensuring fair distribution.
Investors who applied can expect the allotment to be finalized by July 17, 2025, with the actual credit of shares to demat accounts likely within 2–3 working days thereafter.
How to Check IPO Allotment Status
Applicants can check their IPO allotment status online using any of the following details:
- Application number
- Permanent Account Number (PAN)
- Demat account/client ID
The status can be checked through:
- The IPO registrar’s portal
- The official stock exchange websites
- Online broker platforms offering allotment status lookup tools
Successful applicants will see “Allotted” next to their name and the number of shares allotted. Those not allotted any shares will receive a refund of the application amount promptly.
Grey Market Premium (GMP) Buzz
There has been a notable grey market premium (GMP) surrounding the Anthem Biosciences IPO, signaling strong demand and investor optimism ahead of the listing. While GMP is unofficial and not regulated, it often reflects investor sentiment and expected listing performance.
The presence of a consistent premium suggests that investors are expecting the shares to list at a significant upside over the issue price.
Listing Date and Expectations
The shares of Anthem Biosciences are scheduled to be listed on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on July 19, 2025. Market analysts are closely watching this debut, expecting robust trading activity on listing day.
Factors that could influence the stock’s performance post-listing include:
- Company’s financials and growth potential
- Global demand for pharmaceutical outsourcing
- Industry sentiment and market conditions
What This Means for Investors
For investors who receive allotment, the focus will shift to the listing day and price movement. For those who miss out, the strong market debut could still offer a chance to invest, depending on post-listing performance and valuation.
Anthem Biosciences’ IPO is not just a financial event—it represents a vote of confidence in India’s biotechnology and pharmaceutical innovation, especially in a post-pandemic world that values health and science more than ever.